ALG-093702 / Aligos Therap - LARVOL DELTA

DISCOVERY OF A LIVER TARGETED ORAL PD-L1 SMALL MOLECULE INHIBITOR FOR THE TREATMENT OF CHRONIC HEPATITIS B AND LIVER CANCER (AASLD 2023) - "In the in vivo PD-L1 target occupancy model, oral dosing of ALG-094103 at 50 mg/kg demonstrated higher PD-L1 target occupancy than oral dosing of INCB086550 at 150 mg/kg and IV dosing of durvalumab at 5 mg/kg. We have discovered a novel liver targeted oral PD-L1 small molecule inhibitor, ALG-094103, with similar in vitro potency to ALG-093702 and INCB08655, and with significantly improved oral bioavailability. ALG-094103 will be further evaluated as a potential candidate for drug development."

Gastrointestinal Cancer • Hepatitis B • Hepatology • Infectious Disease • Liver Cancer • Oncology • Solid Tumor

Preclinical pharmacokinetic, pharmacodynamic and efficacy relationships of ALG-093702, a liver targeted PD-L1 small molecule inhibitor, in different in vivo models (EASL-ILC 2023) - "We discovered a liver-targeted PD-L1 small molecule inhibitor, ALG-093702, with similar in vitro potency and in vivo PD-L1 target occupancy and tumor growth inhibition as the PD-L1 antibody drug, durvalumab. The preclinical PK/PD/efficacy correlation provides guidance for the efficacious human dose prediction and dosing strategy for clinical studies of oral liver targeted PD-L1 small molecule inhibitor."

PK/PD data • Preclinical • Hepatitis B • Hepatology • Immune Modulation • Infectious Disease • Oncology • IFNG

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 (GlobeNewswire) - "Aligos Therapeutics...announced that the company is presenting several posters collectively highlighting data from its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023....ALG-093702, a liver-targeted PD-L1 small molecule inhibitor, demonstrated similar in vitro potency and in vivo PD-L1 target occupancy and tumor growth inhibition as the PD-L1 antibody drug, durvalumab. Preclinical pharmacokinetic, pharmacodynamic and efficacy data provided guidance for the efficacious human dose prediction and dosing strategy for clinical studies of oral liver targeted PD-L1 small molecule inhibitors."

Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 (GlobeNewswire) - "Aligos Therapeutics, Inc...announced that the company will present seven posters collectively highlighting data on its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023."

Preclinical • Oncology • Solid Tumor

Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023 (GlobeNewswire) - "Aligos Therapeutics...announced that the company will present seven posters collectively highlighting data out of five of its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023....'We look forward to sharing additional detail at the time of the conference and further results throughout the year'."

Clinical data • Preclinical • Gastrointestinal Cancer • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Liver Cancer • Oncology • Solid Tumor

Discovery of a Liver-Targeted PD-L1 Small Molecule Inhibitor for the Treatment of Chronic Hepatitis B and Liver Cancer (APASL 2023) - "We discovered a liver-targeted PD-L1 small molecule inhibitor, ALG-093702, with a different mechanism of action of PD-1/PD-L1 blockade compared to PD-L1 antibodies. The compound blocked PD-1/PD-L1 interaction while also reducing cell surface PD-L1. ALG-093702 had similar in vivo and ex vivo potency to a PD-L1 antibody drug, durvalumab."

Gastrointestinal Cancer • Hepatitis B • Hepatocellular Cancer • Hepatology • Immune Modulation • Infectious Disease • Liver Cancer • Oncology • Solid Tumor

Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver (GlobeNewswire) - "Aligos’ small molecule liver-targeted PD-L1 inhibitor, ALG-093702, was shown to block the PD-1/PD-L1 interaction while reducing cell surface PD-L1. The compound also demonstrated similar potency to the PD-L1 antibody drug durvalumab."

Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

ALG-093702, an orally available PD-L1 small-molecule inhibitor with efficacy in models of liver cancer (Bioworld) - "Researchers from Aligos Therapeutics Inc. have described the discovery of novel liver-targeted oral PD-L1 small-molecule inhibitors for the treatment of chronic hepatitis B and liver cancers."

New molecule • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology